(Reuters) -Ionis Pharmaceuticals said on Wednesday its experimental drug to treat a type of fatty liver disease met the main goal of reducing inflammation of the […]

To what extent can our intestinal microbiota predict the risk of developing diseases? In the case of multifactorial diseases, bacterial taxa alone do not provide much […]

TOPLINE: Higher dietary niacin intake is associated with a lower risk for all-cause mortality among people with metabolic dysfunction-associated steatotic liver disease (MASLD), but there is […]

TOPLINE: Adherence to a higher number of the five key lifestyle behaviors — not smoking, vigorous physical activity, optimal sleep, high-quality diet, and moderate alcohol consumption […]

Semaglutide improved metabolic dysfunction–associated steatotic liver disease (MASLD) among people living with HIV, and in some cases resolved it completely, according to results from the SLIM […]

Vitamin D levels are unlikely to have an impact on the clinical features of eosinophilic esophagitis (EoE) in adults newly diagnosed with the chronic inflammatory disorder, […]

TOPLINE: The anti-inflammatory shift in mid-pregnancy may be linked to changes in gut microbiota, which, in turn, may wield their influence through fecal and plasma metabolites. […]

(Reuters) -Akero Therapeutics’ experimental drug for a type of fatty liver disease significantly reduced scarring after nearly two years in a mid-stage study, it said on […]